| scholarly article | Q13442814 |
| editorial | Q871232 |
| P356 | DOI | 10.4155/FMC.12.9 |
| P698 | PubMed publication ID | 22416770 |
| P2093 | author name string | Margaret S Lee | |
| P2860 | cites work | Future of personalized medicine in oncology: a systems biology approach | Q33898189 |
| Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma | Q34124932 | ||
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia | Q36047171 | ||
| Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). | Q36263988 | ||
| Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer | Q37774442 | ||
| Benefit-risk assessment of bevacizumab in the treatment of breast cancer. | Q37963955 | ||
| US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics. | Q53266350 | ||
| Crizotinib. | Q54546375 | ||
| P433 | issue | 4 | |
| P921 | main subject | prioritization | Q11888847 |
| P304 | page(s) | 387-389 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | Systematic prioritization of cancer combination therapies: are we really on target? | |
| P478 | volume | 4 |
Search more.